Among the 279 patients who received primary prophylaxis for pneumocystosis, 211 (75.6%) had early discontinuation of prophylaxis, and 68 (24.4%) continued prophylaxis until CD4 increased to ≧200 cells/μL (Table 1). This evidence concerns the gene CD4 and pneumocystosis.